Free Trial

LifeMD, Inc. (NASDAQ:LFMD) Receives Average Rating of "Buy" from Analysts

LifeMD logo with Medical background

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.86.

A number of equities research analysts have weighed in on the stock. Lake Street Capital set a $18.00 price target on shares of LifeMD and gave the company a "buy" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of LifeMD in a report on Wednesday, April 30th. Finally, BTIG Research upped their price target on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, June 18th.

Read Our Latest Report on LifeMD

LifeMD Trading Down 3.7%

LFMD stock traded down $0.44 during trading on Thursday, hitting $11.52. The company had a trading volume of 390,386 shares, compared to its average volume of 1,082,066. The firm has a market capitalization of $523.58 million, a price-to-earnings ratio of -34.00 and a beta of 2.40. The business has a 50 day moving average of $11.71 and a 200 day moving average of $7.72. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $15.84.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to analyst estimates of $62.47 million. As a group, equities analysts predict that LifeMD will post -0.56 EPS for the current year.

Insider Buying and Selling

In other LifeMD news, insider Eric Harold Yecies sold 15,000 shares of the business's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.25, for a total transaction of $183,750.00. Following the sale, the insider owned 16,100 shares in the company, valued at approximately $197,225. The trade was a 48.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stefan Galluppi sold 85,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider owned 80,449 shares in the company, valued at $995,958.62. This represents a 51.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 346,995 shares of company stock worth $4,119,172 in the last quarter. 18.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LifeMD

A number of large investors have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares during the period. Prudential Financial Inc. increased its holdings in shares of LifeMD by 19.3% in the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock valued at $67,000 after purchasing an additional 2,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock valued at $270,000 after buying an additional 2,235 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after buying an additional 2,895 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of LifeMD by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock valued at $4,071,000 after buying an additional 2,984 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.

LifeMD Company Profile

(Get Free Report

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

Featured Articles

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Should You Invest $1,000 in LifeMD Right Now?

Before you consider LifeMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.

While LifeMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines